NCT06721286View on ClinicalTrials.gov

Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 12, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Intrahepatic Cholangiocarcinoma (Icc)
Interventions
DRUG

Teripalimab

240mg intravenous injection, D1, q3w, for 9 weeks (3 cycles)

DRUG

Gemcitabine + Cisplatin

Gemcitabine 1000mg/m2 + cisplatin 25mg/m2, D1\&D8, q3w, for 9 weeks (3 cycles)

PROCEDURE

Surgery

Radical resection

Trial Locations (1)

300060

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER